Business
4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022
4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T. EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"4D Molecular Therapeutics to host a conference call on November 14th, 8:00 am E.T.\nEMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that enrollment has been completed in all 3 cohorts of the Phase 1 Dose Exploration stage of the Phase 1/2 clinical trial of intravitreal 4D-150 in patients with wet AMD (n=15 patients total; 5 patients per cohort). All 3 cohorts have been cleared for safety, with no dose-limiting toxicities (DLTs) being reported. 4D Molecular Therapeutics also announced that interim clinical data from cohort 1 of this Phase 1/2 clinical trial will be released at 7:30 am E.T., on Monday, November 14, 2022. 4D will host a conference call and live webcast on November 14th, 2022, at 8:00 am E.T. to further discuss the interim clinical data. The presentation will include a summary of the following in patients with wet AMD who have been enrolled and treated with 4D-150 in cohort 1 of the Dose Exploration stage of the clinical trial (n=5; 3E10 vg/eye): Safety and tolerability dataAflibercept transgene expression in aqueous humor samplesEfficacy assessments as follows: change in annualized anti-VEGF injection rate after 4D-150 dosing, andPercent of patients who remain supplemental aflibercept injection-free after 4D-150 dosing. Conference Call Information 4D Molecular Therapeutics will host a conference call and live webcast on November 14, 2022, at 8:00 am E.T. to discuss the interim clinical data. Registration and dial-in for the conference call may be accessed through 4D Molecular Therapeutics website under Events & Presentation in the Investors section through the following link: https://ir.4dmoleculartherapeutics.com/events. An archived replay of the webcast will be available following the event. About 4D-150 and wet AMD 4D-150 is comprised of our targeted and evolved intravitreal vector, R100, and a payload that expresses aflibercept and a VEGF-C RNAi. This dual transgene payload inhibits 4 angiogenic factors: VEGF A, B, C and PlGF. 4D-150 is designed for low dose intravitreal delivery. Wet AMD is a type of macular degeneration where abnormal blood vessels (choroidal neovascularization or CNV) grow into the macula, the central area of the r...